{
  "pathway_name": "pancreatic-cancer-clinical-pathways-v2-2024-508h",
  "original_file": "pancreatic-cancer-clinical-pathways-v2-2024-508h_extracted.json",
  "processed_at": "2025-03-29T01:05:48.792339",
  "complete_summary": {
    "response": "# COMPREHENSIVE SUMMARY: PANCREATIC CANCER CLINICAL PATHWAY (VA 2024)\n\n## 1. INITIAL EVALUATION AND DIAGNOSIS\n\n### Diagnostic Approach\n- **Imaging**: Contrast-enhanced CT of chest, abdomen, and pelvis (multiphase imaging preferred)\n- **Biopsy Recommendations**:\n  * At least two attempts to obtain core biopsy of metastatic lesion (if present)\n  * OR EUS with fine needle aspiration of primary tumor\n  * Core biopsy preferred when possible to confirm diagnosis and obtain tissue for molecular testing\n  * Include cell block for molecular testing\n\n### Initial Categorization\n- Following imaging and possible biopsy, cases undergo multidisciplinary discussion to determine:\n  * Resectable disease\n  * Borderline resectable disease\n  * Locally unresectable disease (Stage III)\n  * Metastatic disease (Stage IV)\n\n## 2. MOLECULAR TESTING RECOMMENDATIONS\n\n### Testing Eligibility\n- All patients with pathologically confirmed pancreatic cancer\n- Patients with family history of chronic pancreatitis OR personal history of unexplained chronic pancreatitis\n\n### Testing Strategy\n- **For Unresectable/Metastatic Disease**:\n  * Obtain germline testing\n  * Assess tumor tissue availability\n    - If adequate: Proceed to molecular testing\n    - If inadequate: Assess feasibility of rebiopsy\n      * If rebiopsy feasible: Perform rebiopsy and comprehensive testing\n      * If rebiopsy not feasible: Perform liquid biopsy\n\n- **For Resectable Disease**:\n  * Assess tumor MMR status by IHC and/or MSI by PCR\n\n### Required Testing Components\n- **Germline NGS Testing**:\n  * Required genes: APC, ATM, BRCA1, BRCA2, CDK4, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PMS2, PALB2, STK11, TP53\n  * Additional genes for pancreatitis history: SPINK1, PRSS1, CPA1, CTRC, CFTR\n\n- **Somatic NGS Testing**:\n  * Comprehensive Genomic Profiling (CGP) using DNA and RNA-based methodology\n\n- **IHC Testing**:\n  * MMR proteins: MLH1, MSH2, MSH6, PMS2\n\n## 3. TREATMENT PATHWAYS BY DISEASE STAGE\n\n### A. RESECTABLE PANCREATIC CANCER\n\n#### Initial Steps\n- DPTD (Dihydropyrimidine Dehydrogenase) testing\n- Molecular testing pathway\n- Multidisciplinary discussion\n\n#### Treatment Algorithm\n1. **Assess candidacy for combination chemotherapy**:\n   \n   **IF CANDIDATE**:\n   - Assess for mFOLFIRINOX eligibility\n     * **If eligible**: mFOLFIRINOX \u2192 Evaluate every 2 months with multidisciplinary discussion\n     * **If not eligible**: Nab-paclitaxel + gemcitabine \u2192 Evaluate every 2 months with multidisciplinary discussion\n   \n   **IF NOT CANDIDATE**:\n   - Assess for immediate surgery\n     * **If surgical candidate**: Resection \u2192 Adjuvant chemotherapy\n     * **If not surgical candidate**: Chemo/ChemoRadiation\n\n2. **Post-Neoadjuvant Therapy Assessment**:\n   \n   **IF DISEASE PROGRESSION**:\n   - Check for distant metastasis\n     * **If present**: Follow appropriate staged pathway\n     * **If absent**: Multidisciplinary discussion \u2192 Surgery \u2192 Completion chemotherapy\n   \n   **IF NO PROGRESSION**:\n   - Surgical resection \u2192 Completion chemotherapy\n\n### B. BORDERLINE RESECTABLE PANCREATIC CANCER\n\n#### Initial Steps\n- DPTG testing\n- Multidisciplinary discussion\n\n#### Treatment Algorithm\n1. **Assess candidacy for combination chemotherapy**:\n   \n   **IF CANDIDATE**:\n   - Assess for mFOLFIRINOX eligibility\n     * **If eligible**: mFOLFIRINOX\n     * **If not eligible**: Non-cisplatin + gemcitabine regimen\n   \n   **IF NOT CANDIDATE**:\n   - Single-agent gemcitabine\n\n2. **Monitoring and Reassessment**:\n   - Evaluate every 2 months with multidisciplinary discussion\n   - Assess if patient has become resectable\n     * **If resectable**: Follow opportunity window\n     * **If not resectable**: Refer to Radiation Oncology OR Surgery\n\n3. **Surgical Evaluation**:\n   - Assess surgical candidacy\n     * **If candidate**: Resection \u2192 Adjuvant chemotherapy\n     * **If not candidate**: Continue systemic therapy\n\n### C. STAGE III UNRESECTABLE PANCREATIC CANCER\n\n#### Initial Step\n- DPD testing\n\n#### Treatment Algorithm\n1. **Assess candidacy for combination chemotherapy**:\n   \n   **IF CANDIDATE**:\n   - Assess for mFOLFIRINOX eligibility\n     * **If eligible**: mFOLFIRINOX\n     * **If not eligible**: Gemcitabine-based combination therapy\n   \n   **IF NOT CANDIDATE**:\n   - Single-agent gemcitabine\n\n2. **Monitoring and Reassessment**:\n   - Evaluate every 2 months with multidisciplinary discussion\n   - Assess for distant metastases\n     * **If present**: Transition to appropriately staged pathway\n     * **If absent**: Multidisciplinary discussion for chemoradiation recommendation\n       - **If recommended**: Proceed with chemoradiation\n       - **If not recommended**: Continue current therapy until progression\n\n### D. STAGE IV PANCREATIC CANCER - FIT FOR COMBINATION CHEMOTHERAPY\n\n#### Initial Steps\n- DPYD testing\n- First/Second-line treatment planning\n\n#### First-Line Treatment\n1. **Assess mFOLFIRINOX candidacy**:\n   \n   **IF CANDIDATE**:\n   - mFOLFIRINOX + Molecular testing pathway\n   \n   **IF NOT CANDIDATE**:\n   - Check germline BRCA1/2 or PALB2 status\n     * **If mutated**: Cisplatin + gemcitabine\n     * **If no targetable alterations**: Nab-paclitaxel + gemcitabine\n\n2. **Disease Progression/Toxicity Management**:\n   \n   **AFTER mFOLFIRINOX**:\n   - **If progression/toxicity**: Check molecular subtype\n     * dMMR: Pembrolizumab\n     * NTRK fusion: Entrectinib\n     * No targetable alterations: Nab-paclitaxel + gemcitabine\n   \n   - **If no progression/toxicity**: Check molecular subtype\n     * BRCA1/2wt and PALB2wt: Continue chemotherapy as tolerated\n     * BRCA1/2mut or PALB2mut: Olaparib maintenance\n   \n   **AFTER NON-mFOLFIRINOX THERAPY**:\n   - **If progression/toxicity**: Check molecular subtype\n     * dMMR: Pembrolizumab\n     * NTRK fusion: Entrectinib\n     * No targetable alterations: 5-fluorouracil based combination\n   \n   - **If no progression/toxicity**: Continue chemotherapy as tolerated\n\n### E. STAGE IV PANCREATIC CANCER - SUBSEQUENT LINES\n\n#### Initial Assessment\n- KRAS G12C mutation status\n\n#### Treatment Algorithm\n1. **If KRAS G12C mutation present**:\n   - Adagrasib\n\n2. **If KRAS G12C mutation absent**:\n   - Assess prior progression on 5-FU containing regimens\n     \n     **IF PRIOR PROGRESSION ON 5-FU**:\n     - Assess prior progression on nab-paclitaxel + gemcitabine\n       * **If prior progression**: Consider targeted therapy (especially for BRAF V600E or KRAS G12C mutations) OR Gemcitabine + cisplatin (for germline BRCA1/2 or PALB2 alterations) OR Nab-paclitaxel + gemcitabine\n       * **If no prior progression**: Nab-paclitaxel + gemcitabine\n     \n     **IF NO PRIOR PROGRESSION ON 5-FU**:\n     - DPYD testing (if not already done)\n     - Treatment options:\n       * mFOLFOX6\n       * FOLFIRI\n       * Liposomal irinotecan + 5-FU + leucovorin (after prior gemcitabine with no prior irinotecan)\n       * 5-FU or capecitabine\n\n### F. STAGE IV PANCREATIC CANCER - UNFIT FOR COMBINATION CHEMOTHERAPY\n\n#### Initial Assessment\n- Molecular alteration subtype testing\n\n#### Treatment Algorithm Based on Molecular Alterations\n1. **dMMR Positive**:\n   - First-line: Pembrolizumab\n   - Second-line (if intolerant/progressed): Gemcitabine\n\n2. **NTRK Fusion Positive**:\n   - First-line: Entrectinib\n   - Second-line (if intolerant/progressed): Gemcitabine\n\n3. **Other Molecular Alterations**:\n   - Precision Oncology Consultation\n   - Treatment: Gemcitabine (following consultation recommendations)\n\n4. **No Targetable Mutation**:\n   - First-line: Gemcitabine\n   - DPYD testing prior to second-line\n   - Second-line: 5-FU or Capecitabine (based on DPYD results)\n\n### G. COMPLETELY RESECTED PANCREATIC CANCER (ADJUVANT THERAPY)\n\n#### Treatment Algorithm\n1. **Assess candidacy for combination chemotherapy**:\n   \n   **IF NOT CANDIDATE**:\n   - Single-agent gemcitabine (6 months)\n   \n   **IF CANDIDATE**:\n   - Assess mFOLFIRINOX candidacy\n     * **If candidate**: DPYD testing \u2192 mFOLFIRINOX (6 months)\n     * **If not candidate**: Gemcitabine-based combination (6 months)\n       - Options: Gemcitabine + capecitabine OR Nab-paclitaxel + gemcitabine\n\n2. **Additional Consideration**:\n   - Radiation oncology referral for high-risk patients with:\n     * Positive margin\n     * Perineural invasion\n     * Poor differentiation\n     * Positive lymph nodes\n\n## 4. IMPORTANT CLINICAL PARAMETERS\n\n### DPYD/DPD Testing Protocol\n- Required before fluoropyrimidine therapy if not previously done\n- If results predict intermediate or poor metabolizer status, consult with pharmacist\n- May proceed without results if withholding chemotherapy for 2-3 weeks would endanger patient with high disease burden\n\n### Treatment Eligibility Criteria\n- **Combination Chemotherapy Candidate**:\n  * Baseline ECOG PS 0-2\n  * Adequate organ function and blood counts\n  * Ability to maintain ongoing PO intake\n  * Absence of concurrent medical problems\n\n- **mFOLFIRINOX Candidate**:\n  * ECOG PS 0-1\n  * Absence of uncontrolled CAD\n  * Lack of prohibitive neuropathy\n  * Commitment to bi-weekly visits and ambulatory infusion pump\n\n### Adjuvant/Completion Chemotherapy\n- Recommend total of 6 months (neoadjuvant + adjuvant)\n- Options: 12 cycles of mFOLFIRINOX (every 14 days) OR 6 cycles of gemcitabine-based therapy (every 28 days)\n\n### Clinical Trials Consideration\n- Clinical trials should always be considered throughout all pathways\n- For assistance finding trials: CancerClinicalTrialsNavigation@va.gov\n\n## 5. KEY ABBREVIATIONS\n\n- CGP: Comprehensive Genomic Profiling\n- dMMR: Deficient Mismatch Repair\n- DPYD/DPD: Dihydropyrimidine Dehydrogenase\n- EUS: Endoscopic Ultrasound\n- IHC: Immunohistochemistry\n- MSI: Microsatellite Instability\n- NTRK: Neurotrophic Tyrosine Receptor Kinase\n- PCR: Polymerase Chain Reaction\n\nThis clinical pathway provides comprehensive, evidence-based guidance for the multidisciplinary management of pancreatic cancer across all stages of disease, with emphasis on appropriate molecular testing to inform personalized treatment decisions.",
    "thinking": "Based on the analyses provided for the various pages of the document, I can now synthesize a comprehensive summary of the pancreatic cancer clinical pathway. I'll organize this information in a structured format that would be useful for clinicians, including all key decision points, treatment options, diagnostic criteria, and clinical workflows from the pathway.\n\nFirst, let me outline the major sections that should be included in this comprehensive summary:\n\n1. Introduction/Overview\n2. Initial Evaluation and Diagnosis\n3. Assessment of Resectability\n4. Treatment Pathways by Disease Stage:\n   - Resectable Pancreatic Cancer\n   - Borderline Resectable Pancreatic Cancer\n   - Stage III Unresectable Pancreatic Cancer\n   - Stage IV Pancreatic Cancer (Metastatic)\n     - Fit for combination chemotherapy\n     - Unfit for combination chemotherapy\n     - Subsequent lines of therapy\n5. Completely Resected Disease (Adjuvant Therapy)\n6. Molecular Testing Recommendations\n7. Special Considerations and Definitions\n\nNow I'll develop each section based on the information provided in the analyses:\n\n## 1. Introduction/Overview\n\nThis appears to be a comprehensive clinical pathway for the management of pancreatic cancer from the Veterans Affairs (VA) healthcare system, version 2 from 2024. The pathway covers the entire spectrum of pancreatic cancer management from initial evaluation through various treatment stages and molecular testing.\n\n## 2. Initial Evaluation and Diagnosis\n\nFrom the PAGE 4 ANALYSIS, the initial evaluation process includes:\n\n- Starting with suspected pancreatic cancer\n- Performing contrast-enhanced CT of chest, abdomen, and pelvis (with multiphase imaging preferred)\n- Assessing for metastatic disease\n  - If metastatic disease is present: Proceed to biopsy, molecular testing, and appropriate staging pathway\n  - If no metastatic disease: Proceed to multidisciplinary discussion for categorization as locally unresectable, borderline resectable, or resectable\n- For borderline resectable cases: Biopsy as clinically appropriate and follow molecular testing pathway\n\nBiopsy recommendations include:\n- At least two attempts to obtain core biopsy of metastatic lesion (preferred if feasible)\n- Or EUS with fine needle aspiration of the primary tumor\n- Core biopsy is preferable to confirm diagnosis and obtain tissue for molecular testing\n- Include cell block for molecular testing purposes\n\n## 3. Assessment of Resectability\n\nThis involves multidisciplinary discussion including tumor board or surgeon with required expertise. The assessment categorizes patients into:\n- Resectable\n- Borderline resectable\n- Locally unresectable (Stage III)\n- Metastatic (Stage IV)\n\n## 4. Treatment Pathways by Disease Stage\n\n### Resectable Pancreatic Cancer (PAGE 5 ANALYSIS)\n\nInitial Steps:\n- Dihydropyrimidine Dehydrogenase (DPTD) testing\n- Molecular testing pathway\n- Multidisciplinary discussion\n\nTreatment Decision Tree:\n1. Assess candidacy for combination chemotherapy\n   - If candidate, assess for mFOLFIRINOX\n     - If candidate for mFOLFIRINOX: Administer mFOLFIRINOX\n     - If not candidate for mFOLFIRINOX: Administer Nab-paclitaxel and gemcitabine\n     - Evaluation every 2 months with multidisciplinary discussion\n   - If not candidate for combination chemotherapy, assess for immediate surgery\n     - If candidate for surgery: Proceed to resection followed by adjuvant chemotherapy\n     - If not candidate for surgery: Proceed to chemo/chemoradiation\n\nPost-Neoadjuvant Therapy Assessment:\n- If disease progression: Assess for distant metastasis\n  - If distant metastasis: Follow appropriate staged pathway\n  - If no distant metastasis: Multidisciplinary discussion \u2192 Surgery \u2192 Completion chemotherapy\n- If no disease progression: Proceed to surgical resection \u2192 Completion chemotherapy\n\nKey Definitions:\n- Combination Chemotherapy Candidate: Baseline ECOG PS 0-2, adequate organ function, blood counts per regimen, absence of concurrent medical problems jeopardizing safety\n- mFOLFIRINOX Candidate: ECOG PS 0-1, absence of uncontrolled CAD, adequate renal/hepatic function, committed to bi-weekly visits\n- Adjuvant/Completion Chemotherapy: Total of 6 months (neoadjuvant + adjuvant); options include 12 cycles of mFOLFIRINOX or 6 cycles of gemcitabine-based therapy\n\n### Borderline Resectable Pancreatic Cancer (PAGE 6 ANALYSIS)\n\nInitial Steps:\n- DPTG (Dihydropyrimidine Dehydrogenase) testing\n- Multidisciplinary discussion\n\nTreatment Decision Tree:\n1. Assess candidacy for combination chemotherapy\n   - If candidate, assess for mFOLFIRINOX\n     - If candidate for mFOLFIRINOX: Administer mFOLFIRINOX\n     - If not candidate for mFOLFIRINOX: Administer non-cisplatin and gemcitabine regimen\n   - If not candidate for combination chemotherapy: Administer single-agent gemcitabine\n\nMonitoring and Reassessment:\n- Evaluate every 2 months with multidisciplinary discussion\n- Assess if patient has become resectable\n  - If resectable: Follow opportunity window\n  - If not resectable: Either refer to radiation oncology or refer to surgery\n\nSurgical Evaluation:\n- Assess candidacy for surgery\n  - If candidate: Proceed to resection \u2192 Adjuvant chemotherapy\n  - If not candidate: Continue systemic therapy\n\n### Stage III Unresectable Pancreatic Cancer (PAGE 7 ANALYSIS)\n\nInitial Steps:\n- DPD (Dihydropyrimidine Dehydrogenase) testing\n\nTreatment Decision Tree:\n1. Assess candidacy for combination chemotherapy\n   - If candidate, assess for mFOLFIRINOX\n     - If candidate for mFOLFIRINOX: Administer mFOLFIRINOX\n     - If not candidate for mFOLFIRINOX: Administer gemcitabine-based combination therapy\n   - If not candidate for combination chemotherapy: Administer single-agent gemcitabine\n\nMonitoring and Reassessment:\n- Evaluate every 2 months with multidisciplinary discussion\n- Assess for distant metastases\n  - If distant metastases detected: Transition to appropriately staged pathway\n  - If no distant metastases: Proceed to multidisciplinary discussion\n    - If chemoradiation recommended: Proceed with chemoradiation\n    - If chemoradiation not recommended: Continue current therapy until progression\n\n### Stage IV Pancreatic Cancer - Fit for Combination Chemotherapy (PAGE 8 ANALYSIS)\n\nInitial Steps:\n- DPYD testing\n- Assess candidacy for mFOLFIRINOX\n\nFirst-Line Treatment:\n1. If mFOLFIRINOX candidate:\n   - Administer mFOLFIRINOX\n   - Follow molecular testing pathway in parallel\n2. If not mFOLFIRINOX candidate:\n   - Check germline BRCA1/2 or PALB2 status\n     - If mutated: Cisplatin and gemcitabine\n     - If no targetable alterations: Nab-paclitaxel and gemcitabine\n\nAlternative Pathway:\n- Refer to palliative care (option available throughout pathway)\n\nDisease Progression/Toxicity Management:\n1. After mFOLFIRINOX:\n   - If progression/toxicity: Check molecular alteration subtype\n     - If dMMR: Pembrolizumab\n     - If NTRK fusion: Entrectinib\n     - If no targetable alterations: Nab-paclitaxel and gemcitabine\n   - If no progression/toxicity: Check molecular alterations\n     - If BRCA1/2wt and PALB2wt: Continue chemotherapy as tolerated\n     - If BRCA1/2mut or PALB2mut: Olaparib maintenance\n\n2. After non-mFOLFIRINOX first-line therapy:\n   - If progression/toxicity: Check molecular alteration subtype\n     - If dMMR: Pembrolizumab\n     - If NTRK fusion: Entrectinib\n     - If no targetable alterations: 5-fluorouracil based combination\n   - If no progression/toxicity: Continue chemotherapy as tolerated\n\n### Stage IV Pancreatic Cancer - Subsequent Lines (PAGE 9 ANALYSIS)\n\nInitial Assessment:\n- KRAS G12C mutation status\n\nTreatment Decision Tree:\n1. If KRAS G12C mutation present:\n   - Administer Adagrasib\n2. If KRAS G12C mutation absent:\n   - Assess prior progression on 5-fluorouracil containing regimens\n     - If prior progression on 5-FU:\n       - Assess prior progression on nab-paclitaxel and gemcitabine\n         - If prior progression on nab-paclitaxel and gemcitabine:\n           - Consider targeted therapy (especially for BRAF V600E or KRAS G12C mutations)\n           - OR Gemcitabine and cisplatin (for patients with germline BRCA1/2 or PALB2 alterations who didn't receive cisplatin in first-line)\n           - OR Nab-paclitaxel and gemcitabine\n         - If no prior progression on nab-paclitaxel and gemcitabine:\n           - Nab-paclitaxel and gemcitabine\n     - If no prior progression on 5-FU:\n       - Perform DPYD testing (if not already done)\n       - Options include:\n         - mFOLFOX6\n         - FOLFIRI\n         - Liposomal irinotecan + 5-fluorouracil + leucovorin (after prior gemcitabine-based therapy with no prior irinotecan)\n         - 5-fluorouracil or capecitabine\n\nAdditional Pathway Option:\n- Refer to palliative care (available at any point in the pathway)\n\n### Stage IV Pancreatic Cancer - Unfit for Combination Chemotherapy (PAGE 10 ANALYSIS)\n\nInitial Assessment:\n- Molecular alteration subtype testing (includes either somatic or germline testing)\n\nFirst-Line Treatment Based on Molecular Alterations:\n1. dMMR Positive:\n   - First-line: Pembrolizumab\n   - Second-line (if intolerant or progressed): Gemcitabine\n2. NTRK Fusion Positive:\n   - First-line: Entrectinib\n   - Second-line (if intolerant or progressed): Gemcitabine\n3. Other Molecular Alterations:\n   - Precision Oncology Consultation\n   - Treatment: Gemcitabine (likely following consultation recommendations)\n4. No Targeted Mutation:\n   - First-line: Gemcitabine\n   - DPYD testing prior to second-line therapy\n   - Second-line: 5-Fluorouracil or Capecitabine (based on DPYD testing results)\n\n## 5. Completely Resected Disease - Adjuvant Therapy (PAGE 11 ANALYSIS)\n\nInitial Assessment:\n- Assess candidacy for combination chemotherapy\n\nTreatment Decision Tree:\n1. If not a candidate for combination chemotherapy:\n   - Single-agent gemcitabine (6 months)\n2. If a candidate for combination chemotherapy:\n   - Assess candidacy for mFOLFIRINOX\n     - If mFOLFIRINOX candidate: DPYD testing \u2192 mFOLFIRINOX (6 months)\n     - If not mFOLFIRINOX candidate: Gemcitabine-based combination chemotherapy (6 months)\n       - Options include gemcitabine and capecitabine or nab-paclitaxel and gemcitabine\n\nAdditional Considerations:\n- Consider radiation oncology referral for select high-risk patients with:\n  - Positive margin\n  - Perineural invasion\n  - Poor differentiation\n  - Positive lymph nodes\n\n## 6. Molecular Testing Recommendations (PAGES 12-13 ANALYSIS)\n\nInitial Eligibility:\n1. All patients with pathologically confirmed pancreatic cancer\n2. Patients with family history of chronic pancreatitis OR personal history of chronic unexplained pancreatitis\n\nTesting Pathways:\n1. Disease Status Evaluation:\n   - If locally unresectable or metastatic:\n     - Obtain germline testing\n     - Assess tumor tissue availability\n       - If adequate tumor tissue available: Proceed to molecular testing\n       - If inadequate tumor tissue:\n         - Assess rebiopsy feasibility\n           - If rebiopsy feasible: Perform rebiopsy of primary or metastatic site, perform CGP, MMR, and HER2 status by IHC\n           - If rebiopsy not feasible: Perform liquid biopsy\n   - If resectable disease:\n     - Assess tumor MMR status by IHC and/or MSI by PCR\n\nSpecific Testing Recommendations:\n1. Germline NGS Testing:\n   - Specimen: Blood or saliva\n   - Recommended vendors: Fulgent, Prevention Genetics\n   - Required genes: APC, ATM, BRCA1, BRCA2, CDK4, CDKN2A, EPCAM (deletion), MLH1, MSH2, MSH6, PMS2, PALB2, STK11, TP53\n   - For pancreatitis history, additional genes: SPINK1, PRSS1, CPA1, CTRC, CFTR\n\n2. Somatic NGS Testing:\n   - Test type: CGP using both DNA and RNA based methodology\n   - Specimen: Tumor tissue (preferred) or blood if tissue insufficient\n   - Recommended vendors: Tempus, Foundation Medicine\n\n3. IHC Testing:\n   - Test for MLH1, MSH2, MSH6, PMS2\n   - Specimen: Tumor tissue\n   - Recommended vendor: Tempus (MMR)\n\n## 7. Special Considerations and Definitions\n\nDPD/DPYD Testing Protocol:\n- If not already performed, testing results inform phenotype/genotype assessment\n- Required for therapeutic recommendations if not already performed\n- Particularly important in cases with high toxicity risk\n- Clinicians may proceed without results if withholding chemotherapy for 2-3 weeks would gravely endanger patient\n\nCombination Chemotherapy Candidate Definition:\n- Baseline ECOG PS 0-2\n- Adequate end-organ function and blood counts\n- Ability to maintain ongoing PO intake\n- Absence of intercurrent medical problems\n\nmFOLFIRINOX Candidate Definition:\n- ECOG PS 0-1\n- Absence of uncontrolled CAD\n- Lack of prohibitive neuropathy\n- Patient commitment to bi-weekly clinic visits and ambulatory infusion pump\n\nChemoradiation/Radiation Options:\n- Conventional or moderately hypofractionated doses\n- Typically uses 5-fluorouracil/capecitabine with radiation\n- 50 Gray with a total of 5 months of systemic drug administration\n\nAdjuvant Chemotherapy Recommendations:\n- Total of 6 months (neoadjuvant + adjuvant)\n- Options include 12 cycles of mFOLFIRINOX (every 14 days) or 6 cycles of gemcitabine-based chemotherapy (every 28 days)\n\nClinical Trials:\n- Should always be considered throughout all pathways\n- For assistance finding appropriate trials, email CancerClinicalTrialsNavigation@va.gov\n\nAbbreviations:\n- CGP: Comprehensive Genomic Profiling\n- dMMR: Deficient Mismatch Repair\n- DPYD/DPD: Dihydropyrimidine Dehydrogenase\n- EUS: Endoscopic Ultrasound\n- IHC: Immunohistochemistry\n- MSI: Microsatellite Instability\n- NTRK: Neurotrophic Tyrosine Receptor Kinase\n- PCR: Polymerase Chain Reaction\n\nNow I'll compile this information into a comprehensive, organized summary that would serve as a definitive reference for the entire pathway."
  }
}